Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Triple meeting – the point of turning to TPX-0022
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Esmo 2020 movers – antibody drug conjugates dominate the news flow
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Roche pits its targeted cancer Blueprint against Lilly
Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.
